Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report

Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report

The current Food and Drug Administration-approved systemic treatments for advanced hepatocellular carcinoma (HCC) include multikinase inhibitors (tyrosine kinase inhibitor [TKI]) and immune checkpoint inhibitors (ICIs). Among ICIs, nivolumab is used as second-line therapy for advanced HCC after sora...

Full description

Bibliographic Details
Main Authors:	Ji Eun Han, Hyo Jung Cho, Soon Sun Kim, Jae Youn Cheong
Format:	Article
Language:	English
Published:	Korean Liver Cancer Association 2021-09-01
Series:	Journal of Liver Cancer
Subjects:	nivolumab immune checkpoint inhibitor advanced hepatocellular carcinoma case report
Online Access:	http://e-jlc.org/upload/pdf/jlc-2021-08-26.pdf

Similar Items

Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery
by: Peilin Dai, et al.
Published: (2022-06-01)

Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma
by: Tsai-Hung Yen, et al.
Published: (2020-07-01)

Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report
by: Takeshi Okamoto, et al.
Published: (2021-07-01)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
by: Yen-Hao Chen, et al.
Published: (2023-08-01)

Low-dose nivolumab in advanced hepatocellular carcinoma
by: Yen-Hao Chen, et al.
Published: (2022-11-01)

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Yan Li, et al.
Published: (2022-07-01)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma
by: M. N. Khagazheeva, et al.
Published: (2022-06-01)

A Case of Advanced Gastric Cancer with Peritoneal Metastasis Treated Successfully with Nivolumab
by: Hirofumi Tazawa, et al.
Published: (2019-07-01)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
by: Hsin-Yu Kuo, et al.
Published: (2022-10-01)

Isolated Right Ventricular Metastasis in a Woman with Advanced Hepatocellular Carcinoma after Palliative Therapy
by: Chun-Ting Fan, et al.
Published: (2019-11-01)

Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study
by: Bo Hyun Kim, et al.
Published: (2024-04-01)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
by: Yuan-Hung Kuo, et al.
Published: (2021-05-01)

Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors
by: A. Yu. Goryainova, et al.
Published: (2021-12-01)

Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma
by: Shih-Hung Yang, et al.
Published: (2022-04-01)

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
by: Mikako Nakamura, et al.
Published: (2023-02-01)

Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma
by: Ahmad A. Tarhini, et al.
Published: (2022-11-01)

Concurrent transarterial radioembolization and combination atezolizumab/bevacizumab treatment of infiltrative hepatocellular carcinoma with portal vein tumor thrombosis: a case report
by: Min Kyung Park, et al.
Published: (2022-03-01)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
by: Francesco Tovoli, et al.
Published: (2020-10-01)

Contemplation of the Effect of Nivolumab Plus Cabosantinib Therapy on Cerebral Hemorrhage in Patients with Brain Metastasis of Renal Cell Carcinoma: A Case Report
by: Yasufumi Sato, et al.
Published: (2023-12-01)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
by: Pramod Savarapu, et al.
Published: (2021-11-01)

Nivolumab-Induced de novo Discoid Lupus Erythematosus
by: Jaya Manjunath, et al.
Published: (2022-04-01)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
by: Hyung Jun Kim, et al.
Published: (2023-03-01)

Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report
by: Tomoya Takami, et al.
Published: (2021-12-01)

Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review
by: Ryota Mori, et al.
Published: (2022-05-01)

Clinical utility of nivolumab in the treatment of advanced melanoma
by: Asmar R, et al.
Published: (2016-02-01)

Molecular Farming of Pembrolizumab and Nivolumab
by: Michael C. Stark, et al.
Published: (2023-06-01)

Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection
by: Pil Soo Sung, et al.
Published: (2020-06-01)

Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy
by: Amruth R. Palla, et al.
Published: (2016-11-01)

Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report
by: Sang Youn Hwang, et al.
Published: (2021-09-01)

Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors—A Systematic Review of the Literature
by: Cristina-Florina Pîrlog, et al.
Published: (2022-12-01)

Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab
by: Jianwei Zhang, et al.
Published: (2019-12-01)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
by: Katsuhiro Yoshimura, MD, PhD, et al.
Published: (2021-11-01)

Dabrafenib plus trametinib versus nivolumab for advanced melanoma
by: Daniela Lahoz, et al.
Published: (2023-02-01)

Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report
by: Hélène Pluchart, et al.
Published: (2017-07-01)

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
by: Lucía Vázquez-Montero, et al.
Published: (2023-06-01)

Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab
by: Bond DA, et al.
Published: (2017-05-01)

Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
by: Takuma Imakita, et al.
Published: (2017-01-01)

Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
by: Feifei Wang, et al.
Published: (2021-07-01)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
by: Marcos Oro-Ayude, et al.
Published: (2020-02-01)